Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company engaged in the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company's lead product candidate, azetukalner, is a Kv7 potassium channel opener currently in Phase 3 clinical trials for focal onset seizures, primary generalized tonic-clonic seizures, major depressive disorder, and bipolar depression. Its early-stage pipeline includes Kv7 potassium channel openers and Nav sodium channel modulators, such as XEN1701 and XEN1120, being advanced for pain indications. Founded in 1996 with a focus on identifying genetic targets for human disease, the company transitioned to a publicly traded entity in 2014 to build a fully integrated biotechnology platform. Xenon leverages its heritage in ion channel biology and genetics to develop proprietary medicines, with a strategic emphasis on expanding its pipeline through internal discovery and selective collaborations.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage xenon-pharma.com
Sector Healthcare IR page investor.xenon-pharma.com
Tags
neuroscience, ion channel modulators, epilepsy, major depressive disorder, bipolar depression, pain management, drug discovery, clinical development, kv7 potassium channel openers, nav sodium channel modulators, azetukalner, XEN1701, XEN1120, X-TOLE2, X-TOLE3, X-ACKT, X-NOVA2, X-NOVA3, X-CEED, X-NOVA, X-TOLE
Press page —

Metrics

Valuation  
Market cap $ 3.655B
Market cap (USD) $ 3.655B
P/E -7.91
PEG —
P/BV 3.19
P/S 487.31
P/OCF -10.26
P/FCF -10.23
Dividend yield —
Turnover / mcap —
Returns  
ROE -51.8%
ROI -88.9%
ROIC -71.9%
Profit margin -4,612.1%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 14
Quality score -68.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 7.5M — — 9.434M 18.437M 32.166M 6.829M 671K 311K 1.803M 15.577M 28.37M 27.356M
Net profit -345.91M -234.33M -182.393M -125.373M -78.882M -28.837M -41.595M -34.497M -30.704M -22.997M -15.752M 13.018M 12.032M
Free cash flow -279.917M -184.464M -150.944M -101.324M -71.552M -50.761M -5.872M -35.231M -29.041M -19.846M -18.654M -1.263M -3.478M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 44.82 39.2 46.06 39.43 31.24 15.38 13.11 6.31 2.83 7.7 8.04 19.75 —
Price performance 12m 0.14 -0.15 0.17 0.26 1.03 0.17 1.08 1.23 -0.63 -0.04 -0.59 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 200,000 438,000 256,000 813,000 1.82M 2.77M 986,000 874,000 1.47M —
↳ YoY growth -36.5% +119.0% -41.6% +217.6% +124.1% +51.8% -64.3% -11.4% +68.1%
↳ 5y CAGR -10.3% +30.5% +42.1% +69.1% +17.6% +27.8% +12.6%
Borrowings, current (USD) — 700,000 — 4.65M — — — — — —
Borrowings, non-current (USD) — 6.1M 15M 10.9M — — — — — —
Lease liabilities (USD) — — — 911,000 3.32M 8.26M 10.4M 10.9M 9.02M 7.94M
Cash and deposits (USD) 17.1M 20.5M 67.8M 24.8M 45M 176M 57.2M 149M 143M 199M
Right-of-use assets (USD) — — — 933,000 3.33M 8.06M 10.4M 9.19M 7.94M 6.63M
Net debt (borrowings + leases - cash) (USD) — -13.7M -52.7M -8.31M — — — — — —
Cash flow detail
Operating cash flow (USD) -19.6M -28.7M -34.7M -4.63M -48.1M -69.5M -98.4M -145M -181M -279M
Purchases of property, plant and equipment (USD) -279,000 -315,000 -507,000 -1.24M -2.64M -2.05M -2.89M -5.62M -3.08M -799,000
Change in receivables (cash effect) (USD) 121,000 -232,000 175,000 -653,000 -1.03M -459,000 1.76M 130,000 -614,000 —
Change in payables (cash effect) (USD) 547,000 -3,000 783,000 4.54M 2.02M 2.97M 8.06M 3.93M 8.53M 5.51M
Interest paid (cash effect) (USD) — — -561,000 -917,000 -339,000 0.00 0.00 — — —
Income taxes paid (cash effect) (USD) — — — — — — — — — -8.42M
Share-based compensation (USD) 2.16M 2.24M 2.63M 2.92M 5.68M 10M 20.4M 32.4M 50.7M 53.7M
Operating cash flow before change in receivables (USD) -19.7M -28.5M -34.9M -3.98M -47.1M -69M -100M -145M -181M —
Free cash flow (OCF - PPE - intangibles) (USD) -19.8M -29M -35.2M -5.87M -50.8M -71.6M -101M -151M -184M -280M
Income detail
Research and development expense (USD) 19.8M 25.6M 23.6M 38.8M 50.5M 75.5M 106M 168M 210M 301M
↳ 5y CAGR +19.6% +13.9% +27.0% +27.2% +30.6% +32.8% +47.9% +40.2% +42.9%
Total comprehensive income (USD) -23M — — — -28.8M -78.9M -127M -179M -236M -344M
Comprehensive income to owners (USD) -23M — — — -28.8M -78.9M -127M -179M -236M -344M
Reported Mar 8, 2017 Mar 7, 2018 Mar 6, 2019 Mar 9, 2020 Mar 1, 2023 Mar 1, 2023 Mar 1, 2023 Feb 29, 2024 Feb 27, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026

•Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3 and X-ACKT studies and planned Q1 2027 initiation of Phase 3b/4 X-FIRST study evaluating azetukalner as first add-on ASM

•Enrollment in Phase 3 X-NOVA2 study of azetukalner in MDD completed with topline data readout now expected in December 2026

•Positive Phase 1 data for novel, non-opioid pain programs XEN1701 (NaV1.7) and XEN1120 (KV7) presented at IASP World Congress on Pain support initiating Phase 2 proof-of-concept studies in acute pain; studies expected to initiate in H1 2027

•Cash, cash equivalents and marketable securities of $1.2 billion with cash runway into 2029

•Conference call at 4:30 pm EST today

VANCOUVER, BC and BOSTON, MA, November 9, 2026 (GLOBE NEWSWIRE) – Xenon Pharmaceuticals Inc.

Xenon to Present at Upcoming Investor Conferences Bull 0 Bear 0 Routine

November 3, 2026

PDF Version

VANCOUVER, BC and BOSTON, MA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at four upcoming investor conferences in the fourth quarter of 2026.

  • **Guggenheim 3rd Annual Healthcare Innovation Conference,**Boston, MA Fireside chat: Tuesday, November 10, 2026, 2:30–2:55pm EST

  • **Stifel 2026 Healthcare Conference,**New York, NY Fireside chat: Wednesday, November 11, 2026, 4:40–5:10pm EST

  • **2026 Jefferies Global Healthcare Conference in London,**London, UK Fireside chat: Wednesday, November 18, 2026, 10:30–10:55am GMT (5:30–5:55am EST)

  • 9th Annual Evercore Healthcare Conference, Coral Gables, FL Fireside chat: Tuesday, December 1, 2026, 7:55–8:15am EST

Details about all company presentations, including webcast information, can be found on the Investors section of Xenon's website. When available, webcasts will be posted for replay following the event. The above-listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada and elsewhere. All other trademarks belong to their respective owner.

November 2, 2026

PDF Version

VANCOUVER, BC and BOSTON, MA, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Monday, November 9, 2026.

Company Presentation Details:

| Date: | Monday, November 9, 2026 |

| Time: | 4:30pm EST (2:30pm PCT) |

| Webcast: | Pre-register here |

| Dial-In: | (800) 715-9871 toll-free or (646) 307-1963 for international callers |

| Conference ID: | 8984105 |

A live webcast of the company presentation will be available on the Investors section of Xenon's website and posted for replay following the event. The above-mentioned dates and times are subject to change.

About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada and elsewhere. All other trademarks belong to their respective owner.

Prompts

Xenon Pharmaceuticals Inc. (ticker XENE), listed in United States.

ETFs Holding Xenon Pharmaceuticals Inc.

ETF Weight in ETF Shares Market value As of
MEDI 1.20% 13,433 $ 550.686K Nov 12, 2026
FMED 1.08% 9,266 $ 557.999K Aug 31, 2026
GSC 1.03% 47,540 $ 2.863M Aug 31, 2026
FSML 0.93% 19,200 $ 1.159M Jun 30, 2026
GDOC 0.91% 2,974 $ 179.094K Aug 31, 2026
HRTS 0.90% 8,283 $ 498.802K Aug 31, 2026
MMSC 0.58% 7,336 $ 288.011K Nov 16, 2026
TMED 0.32% 1,216 $ 73.398K Jun 30, 2026
FSEG 0.32% 300 $ 18.108K Jun 30, 2026
TCAF 0.30% 832,118 $ 32.669M Nov 17, 2026
SCDS 0.24% 571 $ 22.143K Nov 17, 2026
FTKI 0.22% 1,450 $ 56.927K Nov 16, 2026
MSSM 0.20% 23,955 $ 1.443M Aug 31, 2026
RUSC 0.20% 2,629 $ 158.686K Jun 30, 2026
RESM 0.17% 106 $ 6,398.16 Jun 30, 2026
ESLG 0.17% 635 $ 39.795K Jul 31, 2026
FESM 0.15% 142,578 $ 8.606M Jun 30, 2026
TMSL 0.13% 56,248 $ 3.395M Jun 30, 2026
FFSM 0.12% 28,362 $ 1.777M Jul 31, 2026
VFMO 0.04% 14,146 $ 851.872K Aug 31, 2026
AVIE 0.03% 143 $ 5,614.18 Nov 16, 2026
NTRL short 0.00% -5,680 $ 0.00 Nov 16, 2026